MFT
NVCR icon

Moisand Fitzgerald Tamayo’s NovoCure NVCR Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$1K – 812
2022
Q2 		$1K Sell
10
-9
-47% -$678 ﹤0.01% 538
2022
Q1 		$2K Buy
+19
New +$1.4K ﹤0.01% 393

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moisand Fitzgerald Tamayo's NVCR Position: Q3 2022 in Review

Moisand Fitzgerald Tamayo sold out of NovoCure (NVCR) in Q3 2022, closing a stake of 10 shares — an estimated $1K sold.

Moisand Fitzgerald Tamayo first reported a position in NVCR in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

  • Moisand Fitzgerald Tamayo reported no remaining NovoCure position as of Q3 2022 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 10 NovoCure shares in Q3 2022, an estimated $1K.
  • Moisand Fitzgerald Tamayo first reported a position in NovoCure in Q1 2022 and held it in 2 quarters.
  • Moisand Fitzgerald Tamayo's NovoCure position peaked at $2K in Q1 2022.
  • 303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2022, filed 26 Oct 2022.